Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,115 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01213472 | Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma | completed | Phase 1 | 33 | GlaxoSmithKlineINDUSTRY | 8 | Oct 9, 2019 | clinicaltrials |
| NCT01004224 | A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies | completed | Phase 1 | 208 | Novartis PharmaceuticalsINDUSTRY | 14 | Oct 4, 2019 | clinicaltrials |
| NCT01723475 |
| First-in-man Dose Escalation Study of BAY2010112 in Patients With Prostate Cancer |
| completed |
| Phase 1 |
| 47 |
| BayerINDUSTRY |
| 2 |
| Sep 27, 2019 |
| clinicaltrials |
| NCT02711345 | A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers. | terminated | Phase 1 | 65 | Novartis PharmaceuticalsINDUSTRY | 6 | Sep 19, 2019 | clinicaltrials |
| NCT02745743 | Phase I Trial of BAY1251152 for Advanced Blood Cancers | completed | Phase 1 | 21 | BayerINDUSTRY | 4 | Sep 19, 2019 | clinicaltrials |
| NCT01663857 | A Study LY2228820 for Recurrent Ovarian Cancer | completed | Phase 1 / Phase 2 | 118 | Eli Lilly and CompanyINDUSTRY | 4 | Sep 11, 2019 | clinicaltrials |
| NCT02518113 | A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL | completed | Phase 1 / Phase 2 | 36 | Eli Lilly and CompanyINDUSTRY | 5 | Sep 11, 2019 | clinicaltrials |
| NCT01679405 | BIBW 2992 as add-on to Gem/Cis in Advanced Biliary Tract Cancer | terminated | Phase 1 | 9 | Johannes Gutenberg University MainzOTHER | 1 | Sep 6, 2019 | clinicaltrials |
| NCT02012192 | GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer | terminated | Phase 1 / Phase 2 | 133 | Medical University InnsbruckOTHER | 4 | Aug 13, 2019 | clinicaltrials |
| NCT01363817 | Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma | completed | Phase 1 | 31 | Bristol-Myers SquibbINDUSTRY | 3 | Jul 30, 2019 | clinicaltrials |
| NCT01901432 | A Two-part Study to Assess the Safety and Preliminary Efficacy of Givinostat in Patients With Polycythemia Vera | completed | Phase 1 / Phase 2 | 48 | ItalfarmacoINDUSTRY | 5 | Jul 30, 2019 | clinicaltrials |
| NCT03065023 | Study of Intralesional Administration of MK-4621 (RGT100) in Adult Participants With Advanced or Recurrent Tumors (MK-4621-001/RGT100-001) | terminated | Phase 1 / Phase 2 | 15 | Merck Sharp & Dohme LLCINDUSTRY | 3 | Jul 30, 2019 | clinicaltrials |
| NCT02521376 | Pharmacokinetics of Entospletinib in Adults With Normal and Impaired Liver Function | completed | Phase 1 | 56 | Gilead SciencesINDUSTRY | 3 | Jul 26, 2019 | clinicaltrials |
| NCT02811822 | A Study to Determine the Efficacy, Safety and Pharmacokinetics of GMI-1271 as Adjunct to Standard of Care for the Treatment of Multiple Myeloma | completed | Phase 1 | 10 | GlycoMimetics IncorporatedINDUSTRY | 4 | Jul 10, 2019 | clinicaltrials |
| NCT01543672 | Irradiation of Large Lung Tumors or Two or More Lung Metastases Simultaneously(VOLUMES) | completed | Phase 1 / Phase 2 | 62 | The Netherlands Cancer InstituteOTHER | 4 | Jun 27, 2019 | clinicaltrials |
| NCT02106091 | Safety Study to Assess AFM11 in Patients With Relapsed and/or Refractory CD19 Positive B-cell NHL | terminated | Phase 1 | 16 | Affimed GmbHINDUSTRY | 4 | Jun 18, 2019 | clinicaltrials |
| NCT01648764 | A Study of LY2334737 in Participants With Cancer That is Advanced and/or Has Spread | completed | Phase 1 | 73 | Eli Lilly and CompanyINDUSTRY | 3 | Jun 17, 2019 | clinicaltrials |
| NCT01853228 | A Study of Decitabine (DACOGEN) in Sequential Administration With Cytarabine in Children With Relapsed or Refractory Acute Myeloid Leukemia | terminated | Phase 1 / Phase 2 | 17 | Janssen Research & Development, LLCINDUSTRY | 7 | Jun 17, 2019 | clinicaltrials |
| NCT00634881 | Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia | completed | Phase 1 / Phase 2 | 13 | German CLL Study GroupOTHER | 1 | Jun 13, 2019 | clinicaltrials |
| NCT02106845 | Effect of Regorafenib on Digoxin and Rosuvastatin in Patients With Advanced Solid Malignant Tumors. | completed | Phase 1 | 42 | BayerINDUSTRY | 2 | Jun 7, 2019 | clinicaltrials |
| NCT03127735 | BAY1436032 in Patients With Mutant IDH1(mIDH1) Advanced Acute Myeloid Leukemia (AML) | completed | Phase 1 | 27 | BayerINDUSTRY | 2 | May 14, 2019 | clinicaltrials |
| NCT02253277 | Safety and Tolerability of Combined Treatment With Nilotinib and Ruxolitinib in CML and Ph+ ALL Patients(CoRNea) | completed | Phase 1 | 5 | Novartis PharmaceuticalsINDUSTRY | 1 | May 1, 2019 | clinicaltrials |
| NCT01590199 | Evaluate Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs(MACS2002) | completed | Phase 1 | 18 | Novartis PharmaceuticalsINDUSTRY | 1 | Apr 16, 2019 | clinicaltrials |
| NCT02310243 | Study of Palbociclib in MLL-rearranged Acute Leukemias | unknown | Phase 1 / Phase 2 | 50 | University of UlmOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT01231594 | A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors | completed | Phase 1 | 214 | Novartis PharmaceuticalsINDUSTRY | 9 | Mar 22, 2019 | clinicaltrials |
| NCT00979134 | Study is Designed to Assess the Safety and Tolerability of AZD4547 at Increasing Doses in Patients With Advanced Tumours | terminated | Phase 1 | 95 | AstraZenecaINDUSTRY | 7 | Mar 15, 2019 | clinicaltrials |
| NCT01283516 | A Dose Escalation/Expansion Study of LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase | completed | Phase 1 | 304 | Novartis PharmaceuticalsINDUSTRY | 11 | Mar 15, 2019 | clinicaltrials |
| NCT02751385 | Investigation of the Effect of Nintedanib on the Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Patients With Non-small Cell Lung Cancer | terminated | Phase 1 | 2 | Boehringer IngelheimINDUSTRY | 1 | Mar 14, 2019 | clinicaltrials |
| NCT02808793 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK002 | completed | Phase 1 | 25 | Allakos Inc.INDUSTRY | 1 | Mar 13, 2019 | clinicaltrials |
| NCT02128126 | Study of the Therapeutic Vaccine (ISA101/ISA101b) to Treat Advanced or Recurrent Cervical Cancer(CervISA) | completed | Phase 1 / Phase 2 | 93 | ISA PharmaceuticalsINDUSTRY | 3 | Mar 6, 2019 | clinicaltrials |
| NCT00844064 | Safety and Tolerability of AP 12009, Administered I.V. in Patients With Advanced Tumors Known to Overproduce TGF-beta-2 | completed | Phase 1 | 62 | Isarna Therapeutics GmbHINDUSTRY | 1 | Feb 15, 2019 | clinicaltrials |
| NCT01957644 | Phase I Dose Escalation Trial of Volasertib in Combination With Azacitidine in Patients With MDS or CMML | terminated | Phase 1 | 16 | Boehringer IngelheimINDUSTRY | 2 | Feb 8, 2019 | clinicaltrials |
| NCT02205398 | Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy | terminated | Phase 1 | 13 | Novartis PharmaceuticalsINDUSTRY | 7 | Jan 22, 2019 | clinicaltrials |
| NCT02657447 | Dosimetry Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-02) | withdrawn | Phase 1 | 0 | Nordic NanovectorINDUSTRY | 1 | Jan 10, 2019 | clinicaltrials |
| NCT01258608 | Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 101 | Human Genome Sciences Inc., a GSK CompanyINDUSTRY | 7 | Dec 19, 2018 | clinicaltrials |
| NCT01292603 | A Study to Compare Subcutaneous Versus Intravenous MabThera (Rituximab) in Combination With Chemotherapy in Patients With Chronic Lymphocytic Leukemia | completed | Phase 1 | 240 | Hoffmann-La RocheINDUSTRY | 19 | Dec 19, 2018 | clinicaltrials |
| NCT00073749 | Study Evaluating CMC-544 In B-Cell Non-Hodgkin's Lymphoma | completed | Phase 1 | 79 | PfizerINDUSTRY | 7 | Dec 17, 2018 | clinicaltrials |
| NCT02860780 | A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer | completed | Phase 1 | 9 | Eli Lilly and CompanyINDUSTRY | 2 | Dec 14, 2018 | clinicaltrials |
| NCT01051063 | Evaluation of a New Anti-cancer Immunotherapy in Adult Acute Myeloid Leukemia Patients With a Suboptimal Clinical Response to Induction Chemotherapy | completed | Phase 1 | 17 | GlaxoSmithKlineINDUSTRY | 3 | Nov 29, 2018 | clinicaltrials |
| NCT01265368 | A Clinical Study to Assess Safety and Efficacy of a Tumor Vaccine in Patients With Advanced Renal Cell Carcinoma (ASET)(ASET) | completed | Phase 1 / Phase 2 | 19 | Mologen AGINDUSTRY | 1 | Nov 15, 2018 | clinicaltrials |
| NCT02454634 | Phase I Trial of IDH1 Peptide Vaccine in IDH1R132H-mutated Grade III-IV Gliomas(NOA-16) | completed | Phase 1 | 39 | National Center for Tumor Diseases, HeidelbergOTHER | 1 | Nov 7, 2018 | clinicaltrials |
| NCT01801111 | A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment | completed | Phase 1 / Phase 2 | 138 | Hoffmann-La RocheINDUSTRY | 16 | Nov 2, 2018 | clinicaltrials |
| NCT02718430 | VXM01 Phase I Study in Patients With Metastatic Colorectal Cancer With Liver Metastasis | completed | Phase 1 | 6 | Vaximm GmbHINDUSTRY | 1 | Oct 19, 2018 | clinicaltrials |
| NCT02718443 | VXM01 Phase I Pilot Study in Patients With Operable Recurrence of a Glioblastoma | completed | Phase 1 | 14 | Vaximm GmbHINDUSTRY | 1 | Oct 19, 2018 | clinicaltrials |
| NCT02717884 | Study of Sensitization of Non-M3 AML Blasts to ATRA by Epigenetic Treatment With Tranylcypromine (TCP)(TRANSATRA) | unknown | Phase 1 / Phase 2 | 60 | Michael LuebbertOTHER | 1 | Oct 18, 2018 | clinicaltrials |
| NCT01734304 | DC Vaccination for Postremission Therapy in AML | completed | Phase 1 / Phase 2 | 13 | Ludwig-Maximilians - University of MunichOTHER | 1 | Oct 12, 2018 | clinicaltrials |
| NCT01820325 | Safety and Efficacy of Buparlisib (BKM120) in Patients With Untreated Squamous Non-small Cell Lung Cancer(BASALT-2) | terminated | Phase 1 | 6 | Novartis PharmaceuticalsINDUSTRY | 5 | Oct 11, 2018 | clinicaltrials |
| NCT02550535 | A Phase I/II Study of Gene-modified WT1 TCR Therapy in MDS & AML Patients | completed | Phase 1 / Phase 2 | 3 | Cell Medica LtdINDUSTRY | 3 | Oct 2, 2018 | clinicaltrials |
| NCT02462525 | Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma | terminated | Phase 1 | 74 | AbbVieINDUSTRY | 4 | Sep 13, 2018 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials